Hemogenyx Pharmaceuticals PLC (LON:HEMO)

Founded in 2013, Hemogenyx Pharmaceutical Plc, formerly known as Silver Falcon Plc, is a UK-based biotechnology company that focuses on bringing its cell therapy and immunotherapies to patients in need.  Its principal business is to develop new treatments for serious blood diseases such as severe autoimmune diseases and blood cancer, as well as bone marrow/hematopoietic stem cell transplant market. The company aims to develop a range of products to address current needs to treat blood disorders with bone marrow or hematopoietic stem cell transplants and viral infections, and to advance its therapies through clinical proof-of-concept, taking them towards a final stage of development. The company also licenses therapies to its partners in exchange for potential upfront payments, success milestone, and research funding support and royalty payments. The company’s shares are traded on the London Stock Exchange since 2015 as LON: HEMO.

In US, the company operates through its subsidiary Hemogenyx Pharmaceutical LLC and Immugenyx LLC and in Belgian through, Hemogenyx Cell SPRL. The company is a pre-clinical stage biopharmaceutical business to bring curative power of bone marrow transplantation to patients in need and it offers products and platform technology that support product development. Its product portfolio includes CDX antibody, CAR-T cell therapy, Hu-PHEC stem cell therapy, Humanised mice, undisclosed and CBR Platform. The CDX antibody is a bispecific antibody targeting subset of acute lymphoblastic leukaemia, forms of relapsed/refractory acute myeloid leukaemia (R/R AML) and myelodysplastic syndrome. The CAR-T cell Therapy is a chimeric antigen receptor T-cell that are developed to use in immunotherapy. It also targets R/R AML and can be used as a substitute of transplants to treat blood disorders. Hu-PHEC stem cell therapy also known as Human Post-nasal Hemogenic Endothelial cells generates cancer-free hematopoietic stem cells that are used in treating blood disorders.  

The Humanized mice is a novel type of advanced peripheral blood Hematopoietic chimera that serve as a platform technology to model various diseases for target validation and drug discovery. The Undisclosed is the early-stage programme developed for validation and discovery of therapeutic-like molecules and novel targets to treat Lupus and other autoimmune diseases with Eli Lilly. The CBR platform is recently developed platform that support the treatments for some form of cancer and also for viruses such as SARS-CoV-2, responsible for COBID-19.